Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan Dual Therapy for H. pylori Eradication
NCT07122024Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of keverprazan in Helicobacter pylori infection (3 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: H. pylori eradication rate. Started Feb 2024; status: recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07122024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122024.